<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:ce="http://www.elsevier.com"
    xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"
    xml:lang="en">
    <teiHeader>
        <fileDesc>
            <titleStmt>
                <title level="a" type="main">Recommendations for Treatment for Intermittent Mild
                    Persistent Astma in Children and Adolescents</title>
            </titleStmt>
            <sourceDesc>
                <biblStruct>
                    <analytic>
                        <author type="corresp">
                            <persName>
                                <roleName type="salutation">Prof.</roleName>
                                <forename type="first">Gerd</forename>
                                <forename type="middle">J</forename>
                                <surname>Cropp</surname>
                                <roleName type="degree">M.D.,Ph.D.</roleName>
                            </persName>
                            <email>croppgj@msn.com</email>
                            <affiliation>
                                <orgName type="institution">UCSF</orgName>
                                <orgName type="department">Pediatrics</orgName>
                                <note type="phone">415-476-2072</note>
                                <address><addrLine>521 Parnassus Avenue</addrLine><addrLine>Suite#C344</addrLine><settlement>San Francisco</settlement><region>California</region><country key="US">United States</country><postCode>94143-0632</postCode></address>
                            </affiliation>
                        </author>
                        <author>
                            <persName>
                                <roleName type="salutation">Prof.</roleName>
                                <forename type="first">Charles</forename>
                                <forename type="middle">K.</forename>
                                <surname>Naspitz</surname>
                            </persName>
                            <email>charles@naspitz.com.br</email>
                            <affiliation>
                                <orgName type="institution">Federal University,Sao Paulo</orgName>
                                <orgName type="department">Pediatrics</orgName>
                                <address><settlement>Sao Paulo</settlement><country key="BR">Brazil</country></address>
                            </affiliation>
                        </author>
                        <title level="a" type="main">Recommendations for Treatment for Intermittent
                            Mild Persistent Astma in Children and Adolescents</title>
                    </analytic>
                    <monogr>
                        <title level="j" type="main">Pediatric Pulmonology</title>
                        <idno type="pISSN">8755-6863</idno>
                        <idno type="eISSN">1099-0496</idno>
                        <imprint>
                            <publisher>Pediatric Pulmonology</publisher>
                        </imprint>
                    </monogr>
                    <idno type="pii">PPUL-08-0336</idno>
                </biblStruct>
            </sourceDesc>
        </fileDesc>
    </teiHeader>
    <text>
        <front>
            <div type="abstract">
                <head>Abstract</head>
                <p>Many parents and caretakers of children and adolescents with mild persistent
                    asthma (MPA) do not follow proposed guidelines, namely the daily and continuous
                    administration of inhaled corticosteroids (ICS). Instead, parents and caretakers
                    tend to use ICS and bronchodilators intermittently for short periods and
                    re-start such therapy only when symptoms reappear. It is our opinion that
                    intermittent treatment of MPA in children and adolescents might achieve the same
                    level of asthma control as has been achieved in adults. We propose, therefore,
                    that after an initial period of stabilization with age-appropriate doses of oral
                    glucocorticoids or high-dose ICS and short-acting beta-2 agonists (SABA),
                    caretakers can stop treatment once there are no longer signs or symptoms of
                    asthma. When asthmatic symptoms recur, treatment should be restarted with ICS
                    and SABA, or oral corticosteroids if the exacerbation is severe. The perception
                    of developing asthma symptoms remains an unsolved problem. Based on our clinical
                    experience with asthmatic children and adolescents, we list a number of signs
                    and symptoms that precede an exacerbation of asthma, allowing for an early
                    re-introduction of treatment to prevent an exacerbation. &#xD; &#xD;
                </p>
            </div>
        </front>
        <body/>
        <back/>
    </text>
</TEI>
